Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer

Table 2 Univariate and multivariate analysis by Cox regression analysis for overall survival in patients receiving anti-epidermal growth factor receptor therapy

Covariate	Univariate			Multivariate
	HR	95%CI	P value	HR	95%CI	P value
Age
≥ 65 vs < 65 years	0.83	0.56-1.16	0.242	NA	NA	NA
Female vs male	0.9	0.65-1.25	0.525	NA	NA	NA
ECOG PS
1 vs 0	1.06	0.70-1.62	0.78	NA	NA	NA
2 vs 0	1.19	0.41-3.42	0.748
Underlying disease
Yes vs no	0.91	0.66-1.24	0.54	NA	NA	NA
Histologic subtype
Mucinous vs adenocarcinoma	0.67	0.17-2.72	0.575	0.35	0.08-1.43	0.142
Signet ring cell vs adenocarcinoma	10.74	2.58-44.74	0.001	9.79	2.31-41.57	0.002
Tumor grade
Moderately vs well differentiated	1.12	0.76-1.65	0.557	0.98	0.64-1.50	0.92
Poorly vs well differentiated	2.38	1.24-4.58	0.009	2.18	1.07-4.43	0.032
Metastatic type
Metachronous vs synchronous	0.92	0.59-1.42	0.696	NA	NA	NA
Number of metastases
≥ 2 vs 1 site	1.44	1.05-1.98	0.024	1.44	0.87-2.39	0.161
Liver-limited metastasis
Yes vs no	0.6	0.43-0.84	0.002	1.71	0.92-3.17	0.088
Peritoneal metastasis
Yes vs no	1.85	1.30-2.63	< 0.001	1.31	0.84-2.03	0.233
Anti-EGFR approach
Frontline vs subsequent-line	1.03	0.73-1.46	0.878	1.12	0.79-1.82	0.393
First-line bevacizumab
Yes vs no	0.92	0.64-1.32	0.66	NA	NA	NA
Metastectomy at liver
Yes vs no	0.32	0.22-0.47	< 0.001	0.25	0.15-0.42	< 0.001

ECOG: Eastern Cooperative Oncology Group.